HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration.
What drives the gradual degeneration of dopamine neurons in Parkinson's disease (PD), the second most common neurodegenerative disease, remains elusive. Here, we demonstrated, for the first time, that persistent neuroinflammation was indispensible for such a neurodegenerative process. 1-Methyl-4-phenylpyridinium, lipopolysaccharide (LPS), and rotenone, three toxins often used to create PD models, produced acute but nonprogressive neurotoxicity in neuron-enriched cultures. In the presence of microglia (brain immune cells), these toxins induced progressive dopaminergic neurodegeneration. More importantly, such neurodegeneration was prevented by removing activated microglia. Collectively, chronic neuroinflammation may be a driving force of progressive dopaminergic neurodegeneration. Conversely, ongoing neurodegeneration sustained microglial activation. Microglial activation persisted only in the presence of neuronal damage in LPS-treated neuron-glia cultures but not in LPS-treated mixed-glia cultures. Thus, activated microglia and damaged neurons formed a vicious cycle mediating chronic, progressive neurodegeneration. Mechanistic studies indicated that HMGB1 (high-mobility group box 1), released from inflamed microglia and/or degenerating neurons, bound to microglial Mac1 (macrophage antigen complex 1) and activated nuclear factor-κB pathway and NADPH oxidase to stimulate production of multiple inflammatory and neurotoxic factors. The treatment of microglia with HMGB1 led to membrane translocation of p47(phox) (a cytosolic subunit of NADPH oxidase) and consequent superoxide release, which required the presence of Mac1. Neutralization of HMGB1 and genetic ablation of Mac1 and gp91(phox) (the catalytic submit of NADPH oxidase) blocked the progressive neurodegeneration. Our findings indicated that HMGB1-Mac1-NADPH oxidase signaling axis bridged chronic neuroinflammation and progressive dopaminergic neurodegeneration, thus identifying a mechanistic basis for chronic PD progression.
Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, North Carolina 27709, USA. gao2@niehs.nih.gov
Hui-Ming
HM
Gao
Hui
H
Zhou
Feng
F
Zhang
Belinda C
BC
Wilson
Wayneho
W
Kam
Jau-Shyong
JS
Hong
D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western; D002452:Cell Count; D002458:Cell Fractionation; D002478:Cells, Cultured; D018920:Coculture Techniques; D004298:Dopamine / Q000378:metabolism; D024243:HMGB1 Protein / Q000378:metabolism*; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D018836:Inflammation Mediators / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D016177:Macrophage-1 Antigen / Q000378:metabolism*; D008636:Mesencephalon / Q000166:cytology / Q000378:metabolism; D017628:Microglia / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D019255:NADPH Oxidases / Q000378:metabolism; D009410:Nerve Degeneration / Q000378:metabolism* / Q000473:pathology; D009474:Neurons / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D015398:Signal Transduction
D024243:HMGB1 Protein; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D016177:Macrophage-1 Antigen; D019255:NADPH Oxidases; D004298:Dopamine
FASEB J. 2003 Oct;17(13):1954-6
12897068
Lancet Neurol. 2009 Apr;8(4):382-97
19296921
Biochem Soc Trans. 2007 Nov;35(Pt 5):1127-32
17956294
Science. 2002 Nov 8;298(5596):1241-5
12424381
Ann N Y Acad Sci. 2008 Dec;1147:93-104
19076434
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74
11724929
Glia. 2007 Oct;55(13):1362-73
17654704
J Clin Invest. 2008 Feb;118(2):777-88
18172548
Ann Neurol. 2003 Nov;54(5):599-604
14595649
J Neurochem. 2002 Jun;81(6):1285-97
12068076
Neuron. 2002 Aug 1;35(3):419-32
12165466
J Clin Invest. 2001 Jan;107(1):13-9
11134172
EMBO J. 2010 Jul 7;29(13):2242-52
20526283
J Pharmacol Exp Ther. 2010 Jun;333(3):822-33
20190013
Trends Immunol. 2009 Feb;30(2):91-9
19144568
Br J Pharmacol. 1999 Nov;128(6):1149-58
10578126
Cell. 2010 Mar 19;140(6):918-34
20303880
J Neurosci Res. 2004 Dec 15;78(6):880-91
15499593
Glia. 2007 Apr 1;55(5):453-62
17203472
Trends Neurosci. 1996 Aug;19(8):312-8
8843599
Nat Med. 2010 Apr;16(4):413-9
20348922
J Immunol. 1993 Apr 1;150(7):2972-80
8095957
Brain. 2010 Mar;133(Pt 3):713-26
20157014
J Neurosci. 2008 Nov 12;28(46):12023-12031
19005067
Ann Neurol. 1999 Oct;46(4):598-605
10514096
J Immunol. 2008 Nov 15;181(10):7194-204
18981141
Cell Transplant. 2008;17(4):363-72
18522239
Nat Rev Immunol. 2005 Apr;5(4):331-42
15803152
Nat Rev Neurosci. 2007 Jan;8(1):57-69
17180163
Trends Immunol. 2005 Jul;26(7):388-95
15922663
Clin Exp Immunol. 1993 May;92(2):181-4
8485905
Brain Res Dev Brain Res. 2002 Jan 31;133(1):27-35
11850061
Immunity. 1996 Dec;5(6):653-66
8986723
Nat Med. 2008 May;14(5):501-3
18391963
Nat Rev Neurosci. 2002 Mar;3(3):216-27
11994753
FASEB J. 2003 Oct;17(13):1945-7
14519670
Crit Rev Immunol. 2000;20(3):197-222
10968371
Trends Pharmacol Sci. 2003 Aug;24(8):395-401
12915048
J Exp Med. 1986 Dec 1;164(6):1876-88
3537192
J Neurosci. 2002 Feb 1;22(3):782-90
11826108
Neurology. 1988 Aug;38(8):1285-91
3399080
Neuron. 2006 Feb 16;49(4):489-502
16476660
Science. 2006 Jun 2;312(5778):1389-92
16741123
J Immunol. 2002 Aug 15;169(4):2003-9
12165526
Acta Neuropathol. 1992;84(1):100-4
1502878
Neurosci Lett. 1994 Oct 24;180(2):147-50
7700568
Brain Res. 1997 Sep 12;768(1-2):279-86
9369326
Glia. 2007 Aug 15;55(11):1178-88
17600340
Exp Neurol. 2006 Jun;199(2):499-512
16504177
Cancer Res. 2003 Aug 1;63(15):4724-30
12907655
J Neurosci. 2005 Mar 9;25(10):2566-75
15758166
Nat Med. 2008 May;14(5):504-6
18391962
Arch Neurol. 2007 Jun;64(6):836-40
17562931
Trends Immunol. 2008 Aug;29(8):357-65
18599350
J Neurovirol. 2002 Dec;8(6):480-5
12476343
Annu Rev Immunol. 2010;28:367-88
20192808
Environ Health Perspect. 2003 Jun;111(8):1065-73
12826478
Neurobiol Aging. 2006 Apr;27(4):530-45
16207501
Trends Immunol. 2005 Jul;26(7):381-7
15978523
Nature. 2002 Jul 11;418(6894):191-5
12110890
Mov Disord. 2010;25 Suppl 1:S55-7
20187228
Nat Rev Immunol. 2004 Jun;4(6):469-78
15173835
Nat Med. 2008 May;14(5):507-9
18391961
Nat Med. 1999 Dec;5(12):1403-9
10581083
Nat Neurosci. 2000 Dec;3(12):1301-6
11100151
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):741-9
12921904
J Neurosci. 2006 Jun 14;26(24):6413-21
16775128